NEW YORK, NY--(Marketwire - Nov 13, 2012) - Alliqua, Inc. (OTCQB: [ ALQA ]) ("Alliqua" or the "Company"), an advanced biopharmaceutical company focused on the development, manufacturing and distribution of proprietary transdermal wound care and drug delivery technologies, today announced the launch of a new sales initiative for our proprietary SilverSeal® line of hydrogels. Alliqua will begin the launch at the 9^th annual Desert Foot Conference taking place in Phoenix, Arizona on November 14-16. Desert Foot is a podiatric conference dedicated to serving the needs of providers and clinicians in the VA and Federal Service. Over 500 physicians and service providers are expected to attend this year's conference. Alliqua intends to highlight the effectiveness of its SilverSeal® hydrogels for use with a variety of wounds including dermal/diabetic ulcers, superficial or surgical wounds, first and second degree burns, and skin tears.

Alliqua's manufacturing facility has a current production capacity to support approximately $80 million in sales of hydrogels on an annual basis with room for further expansion. With the overall market for hydrogels expected to exceed $1 billion in the next three years according to MarketsandMarkets, management intends to aggressively build its own proprietary line of hydrogels and provide private label products to other companies to rapidly expand its plant utilization rates. 

Commenting on the marketing efforts, Mr. James Sapirstein, CEO of Alliqua, commented, "As we look to build Alliqua for the future, it is important to focus on two important facets of the company. The launch of this sales effort for our hydrogels is really the low hanging fruit for us in that we have a superior product and the production capability to generate substantial near term revenue without the need for large capital expenditures. If we build that business as we expect we can, we will be able to utilize the cash generated from those operations to invest in the other aspect of our business which is using our platform for drug delivery. We believe that success in drug delivery will enable us to tap into vast pharmaceutical markets and build our company into a truly world class organization for the benefit of our shareholders."

About Alliqua, Inc.
Alliqua, Inc. (ALQA) ("Alliqua") is a biopharmaceutical company focused on the development, manufacturing and distribution of our proprietary transdermal wound care and drug delivery technologies. Alliqua's leading technology platform produces hydrogels, a three dimensional cross-linked network of water soluble polymers capable of numerous chemical configurations. We currently market our new line of 510K FDA approved hydrogel products for wound care under our SilverSeal® brand. Due to our electron beam production process at our 16,000 square foot GMP manufacturing facility, we can aggressively develop and custom manufacture a wide variety of hydrogels. Our hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds such as diabetic ulcers, as well as the delivery of numerous drugs or other agents for the pharmaceutical and cosmetic industries. By using our drug delivery platform in combination with certain drugs, pharmaceutical companies can increase patient compliance as well as potentially extend the life of valuable drug patents. For additional information, please visit [ www.alliqua.com ]. To receive future press releases via email, please visit: [ http://alliqua.com/index.php?page=investor-alerts ].

Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the our control that can make such statements untrue, including, but not limited to, inadequate capital, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K filed with the SEC on March 29, 2012 and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at [ www.sec.gov ]. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.